Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqCM:AGEN
Agenus Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line
Agenus (NASDAQ:AGEN) Full Year 2022 Results
Key Financial Results
- Revenue: US$98.0m (down 67% from FY 2021).
- Net loss: US$230.7m (loss widened by US$206.5m from FY 2021).
- US$0.78 loss per share (further deteriorated from US$0.10 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Agenus Revenues Beat Expectations
Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) was mostly in line with analyst estimates.
Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 15% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 5 warning signs for Agenus you should be aware of, and 2 of them don't sit too well with us.
What are the risks and opportunities for Agenus?
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally.
Rewards
Revenue is forecast to grow 30.64% per year
Risks
Has less than 1 year of cash runway
Negative shareholders equity
Shareholders have been diluted in the past year
Volatile share price over the past 3 months
Currently unprofitable and not forecast to become profitable over the next 3 years
Further research on
Agenus
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:AGEN
Agenus
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally.
Fair value with limited growth.
